We are monitoring the impact of COVID-19 on Latin America Gene Therapy Market Get in touch with us for detailed analysis Know More
Pulished Date July, 2021
ID: 11780
Share on
Share on

Latin America Gene Therapy Market Research Report - Segmented By Vector Type, Application and Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Size, Share, Trends, COVID-19 Impact & Forecast (2021 to 2026)

Pulished: July, 2021
ID: 11780
Pages: 90

Latin America Gene Therapy Market Size (2021 to 2026)

The Latin American gene therapy market size is estimated to be growing at a healthy CAGR during the forecast period.

Gene therapy has become one of the most sought-after research goals for curing incurable diseases. Y-O-Y growth in the prevalence of HIV, cancer, and other hard-to-cure diseases is majorly driving the growth of the Latin American gene therapy market.

The Latin American gene therapy market is expected to be strengthened by a strong product portfolio. The increased funding for major companies is expected to create a positive scenario for development in the years to come. Furthermore, the high incidence of target diseases and the need for innovative drugs are expected to drive the gene therapy market in the future.

The constant investment and consolidation in cell and gene therapy have contributed to the growth of the gene therapy market. After recognizing the potential of the gene therapy market, 16 of the top 20 biopharmaceutical companies by revenue added gene therapy products to their portfolio. In addition, 13% of industrial, clinical development products and at least 17% of products in preclinical development consist of gene therapy products. Furthermore, the constant investments and consolidation of GENE THERAPY's production capacities have led to an increase in production capacities and contributed to the market's growth.

Limited reimbursements that prevent patients from receiving treatments are expected to limit the growth of cell and gene therapy markets in Latin America. The gene therapy market is believed to be small due to the high cost of developing products for various therapies. In addition, strict regulatory policies and a lack of funds by the government are expected to reduce growth momentum over the forecast period.

Impact of COVID-19 on the Latin American gene therapy market:

The use of genetics has been a central tool in understanding the effect of various diseases, including infection with COVID-19. The element of precision in gene therapy is believed to create more opportunities for the market. It can be effectively implemented to treat diseases that have not yet been treated. Currently, available gene therapies are designed to provide an effective treatment option for patients with advanced resistance to chemotherapy in many cancer indications.

The growth is mainly driven by the resumption of operations and businesses adapting to the new normal while recovering from the impact of COVID-19, which previously led to restrictive social distancing containment measures, at work remote and business closures that have created operational challenges.

This research report on the Latin American Gene Therapy Market has been segmented & sub-segmented into the following categories:

 By Vector Type:

  • Viral vector
    • Retroviruses
    • Lentiviruses
    • Adenoviruses
    • Adeno-associated Virus
    • Herpes Simplex Virus
    • Poxvirus
    • Vaccinia Virus
    • Others
  • Non-viral vector
    • Naked/Plasmid Vectors
    • Gene Gun
    • Electroporation
    • Lipofection
    • Others

By Application:

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

The emergence of gene therapies presents a real challenge and an opportunity for regions like Latin America, where countries are already starting to prepare to be part of these research projects and to have patients in clinical trials.

According to a 2019 study, Cuba had the highest cancer rate, affecting 138.4 men and 91.4 women per 100,000. While Mexico had the lowest cancer rate with 64.2 men per 100,000 population and 61.4 women per 100,000 population

The Brazilian gene therapy market is estimated to dominate the Latin American market during the forecast period and accounted for the largest share of 18.4% in 2020 due to the country's economic growth. In addition, Brazil has strategic collaborations with other countries, with initiatives such as the Canada-Brazil Joint Committee for Cooperation in Science, Technology, and Innovation. The Joint Science, Technology, and Innovation Committee are expected to bring together leading experts from the public and private sectors to develop innovative strategies for life sciences and other industrial fields.

The Colombian gene therapy market is another lucrative regional market in the Latin American region and is driven by the continued efforts of Latin American gene therapy and technology companies. For example, in 2019, an international Genetic subsidiary, Veritas Intercontinental, opened an office in Bogotá, Colombia, to manage the company's operations and activities in Colombia and Latin America. This widened the landscape for gene therapy and preventive medicine, ultimately generating income in this region.

KEY MARKET PLAYERS:

Companies such as Biogen, Sarepta Therapeutics, Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Orchard Therapeutics Plc, Spark Therapeutics, Inc., Molmed S.P.A., Anges, Inc., Bluebird Bio, Inc., Jazz Pharmaceuticals Plc, Dynavax Technologies, Human Stem Cells Institute, Sibiono Genetech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Uniqure N.V., Gensight Biologics S.A., Celgene Corporation, Cellectis, Sangamo Therapeutics, Mustang Bio, Applied Genetic Technologies Corporation and Poseida Therapeutics, Inc. are playing a significant role in the Latin American gene therapy market.

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year, and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Report Overview
    1. Executive Summary
    2. Key Inferences
  4. Market Dynamics
    1. Impact Analysis
      1. Drivers
      2. Restraints
      3. Opportunities       
    2. Regulatory Environment
    3. Technology Timeline & Recent Trends
  5. Competitor Benchmarking Analysis
    1. Key Player Benchmarking                    
      1. Market share analysis      
      2. Products/Service
      3. Regional Presence               
    2. Mergers & Acquisition Landscape                     
    3. Joint Ventures & Collaborations
  6. MARKET SEGMENTATION
    1. By Vector Type
      1. Viral vector
        1. Retroviruses
        2. Lentiviruses
        3. Adenoviruses
        4. Adeno-associated Virus
        5. Herpes Simplex Virus
        6. Poxvirus
        7. Vaccinia Virus
        8. Others
      2. Non-viral vector
        1. Naked/Plasmid Vectors
        2. Gene Gun
        3. Electroporation
        4. Lipofection
        5. Others
      3. Y-o-Y Growth Analysis, By Vector Type
      4. Market Attractiveness Analysis, By Vector Type
      5. Market Share Analysis, By Vector Type
    2. By Application
      1. Oncological Disorders
      2. Rare Diseases
      3. Cardiovascular Diseases
      4. Neurological Disorders
      5. Infectious disease
      6. Other Diseases
      7. Y-o-Y Growth Analysis, By Application
      8. Market Attractiveness Analysis, By Application
      9. Market Share Analysis, By Application
  7. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. Latin America
      1. Introduction
      2. Mexico
      3. Brazil
      4. Argentina
      5. Chile
      6. Rest of Latin America
  8. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. The threat of New Entrants
      4. The threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  9. MARKET LEADERS' ANALYSIS
    1. Biogen
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. Sarepta Therapeutics
    3. Gilead Sciences, Inc.
    4. Amgen, Inc.
    5. Novartis AG
    6. Orchard Therapeutics Plc
    7. Spark Therapeutics, Inc.
    8. Molmed S.P.A.
    9. Anges, Inc.
    10. Bluebird Bio, Inc.
    11. Jazz Pharmaceuticals Plc
    12. Dynavax Technologies
    13. Human Stem Cells Institute
    14. Sibiono Genetech Co., Ltd.
    15. Shanghai Sunway Biotech Co., Ltd.
    16. Uniqure N.V.
    17. Gensight Biologics S.A.
    18. Celgene Corporation
    19. Cellectis
    20. Sangamo Therapeutics
    21. Mustang Bio
    22. Applied Genetic Technologies Corporation
    23. Poseida Therapeutics, Inc.
  10. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  11. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  12. APPENDIX
    1. List of Tables
    2. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of vector type and application along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. Middle East and Africa Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  2. Middle East and Africa Viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  3. Middle East and Africa Non-viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  4. Middle East and Africa Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  5. Middle East and Africa Oncological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  6. Middle East and Africa Rare Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  7. Middle East and Africa Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  8. Middle East and Africa Neurological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  9. Middle East and Africa Infectious disease Market, By Region, From 2021 to 2026 (USD Billion)
  10. Middle East and Africa Other Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  11. Middle East Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  12. Middle East Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  13. Africa Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  14. Africa Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  15. Middle East and Africa Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  16. Middle East and Africa Retroviruses Market, By Region, From 2021 to 2026 (USD Billion)
  17. Middle East and Africa Lentiviruses Market, By Region, From 2021 to 2026 (USD Billion)
  18. Middle East and Africa Adenoviruses Market, By Region, From 2021 to 2026 (USD Billion)
  19. Middle East and Africa Adeno-associated Virus Market, By Region, From 2021 to 2026 (USD Billion)
  20. Middle East and Africa Herpes Simplex Virus Market, By Region, From 2021 to 2026 (USD Billion)
  21. Middle East and Africa Poxvirus Market, By Region, From 2021 to 2026 (USD Billion)
  22. Middle East and Africa Vaccinia Virus Market, By Region, From 2021 to 2026 (USD Billion)
  23. Middle East Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  24. Africa Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  25. Middle East and Africa Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  26. Middle East and Africa Naked/Plasmid Vectors Market, By Region, From 2021 to 2026 (USD Billion)
  27. Middle East and Africa Gene Gun Market, By Region, From 2021 to 2026 (USD Billion)
  28. Middle East and Africa Electroporation Market, By Region, From 2021 to 2026 (USD Billion)
  29. Middle East and Africa Lipofection Market, By Region, From 2021 to 2026 (USD Billion)
  30. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  31. Middle East Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  32. Africa Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample